BD raises FY2025 adjusted EPS guidance as Q3 revenue rises 10.4% to $5.5 billion
BD reported third-quarter fiscal 2025 revenue of $5.5 billion, up 10.4% as reported and 3.0% on an organic basis, with GAAP diluted EPS of $2.00 versus $1.68 a year earlier. The company raised its full-year adjusted diluted EPS guidance to $14.30 to $14.45 from $14.06 to $14.34 and reaffirmed its organic revenue growth outlook of 3.0% to 3.5%.
Key points
- Q3 fiscal 2025 revenue of $5.5 billion, up 10.4% as reported; GAAP diluted EPS $2.00 vs. $1.68; adjusted diluted EPS $3.68 vs. $3.50
- GAAP net income of $574 million vs. $487 million in the prior-year quarter
- Full-year adjusted diluted EPS guidance raised to $14.30 to $14.45; organic revenue growth guidance reaffirmed at 3.0% to 3.5%
- Nine-month GAAP net income fell 9.2% to $1.185 billion; a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters Corporation was announced in July
The filing
Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.